These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

731 related articles for article (PubMed ID: 26920914)

  • 21. Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany.
    Steinig I; von Podewils F; Möddel G; Bauer S; Klein KM; Paule E; Reif PS; Willems LM; Zöllner JP; Kunz R; Runge U; Kurlemann G; Schubert-Bast S; Rosenow F; Strzelczyk A
    Epilepsia; 2017 Jul; 58(7):1208-1216. PubMed ID: 28480518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-ictogenic and antiepileptogenic properties of brivaracetam in mature and immature rats.
    Dupuis N; Matagne A; Staelens L; Dournaud P; Desnous B; Gressens P; Auvin S
    Epilepsia; 2015 May; 56(5):800-5. PubMed ID: 25818358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil.
    Wu PP; Cao BR; Tian FY; Gao ZB
    Neurosci Bull; 2024 May; 40(5):594-608. PubMed ID: 37897555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies.
    Moseley BD; Sperling MR; Asadi-Pooya AA; Diaz A; Elmouft S; Schiemann J; Whitesides J
    Epilepsy Res; 2016 Nov; 127():179-185. PubMed ID: 27608437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brivaracetam for the treatment of epilepsy.
    Klein P; Tyrlikova I; Brazdil M; Rektor I
    Expert Opin Pharmacother; 2016; 17(2):283-95. PubMed ID: 26760311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
    Ryvlin P; Werhahn KJ; Blaszczyk B; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):47-56. PubMed ID: 24256083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis.
    Hirsch M; Hintz M; Specht A; Schulze-Bonhage A
    Seizure; 2018 Oct; 61():98-103. PubMed ID: 30118932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physiologically based pharmacokinetic/pharmacodynamic animal-to-man prediction of therapeutic dose in a model of epilepsy.
    Brochot A; Zamacona M; Stockis A
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):256-62. PubMed ID: 20102365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Interactions with Synaptic Vesicle 2 Proteins and the GABA
    Wood M; Daniels V; Provins L; Wolff C; Kaminski RM; Gillard M
    J Pharmacol Exp Ther; 2020 Jan; 372(1):1-10. PubMed ID: 31619465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brivaracetam: a novel antiepileptic drug for focal-onset seizures.
    Stephen LJ; Brodie MJ
    Ther Adv Neurol Disord; 2018; 11():1756285617742081. PubMed ID: 29399049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.
    Matagne A; Margineanu DG; Kenda B; Michel P; Klitgaard H
    Br J Pharmacol; 2008 Aug; 154(8):1662-71. PubMed ID: 18500360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study.
    Menzler K; Mross PM; Rosenow F; Schubert-Bast S; Willems LM; Zahnert F; Immisch I; Fuest S; von Podewils F; Kunz R; Hirsch M; Mueller T; Marquetand J; Winter Y; Langenbruch L; Cicanic M; Beyenburg S; Strzelczyk A; Knake S
    BMJ Open; 2019 Nov; 9(11):e030746. PubMed ID: 31690606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brivaracetam Prevents the Over-expression of Synaptic Vesicle Protein 2A and Rescues the Deficits of Hippocampal Long-term Potentiation In Vivo in Chronic Temporal Lobe Epilepsy Rats.
    Ge YX; Lin YY; Bi QQ; Chen YJ
    Curr Neurovasc Res; 2020; 17(4):354-360. PubMed ID: 32407277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brivaracetam for the treatment of epilepsy in adults.
    Mula M
    Expert Rev Neurother; 2014 Apr; 14(4):361-5. PubMed ID: 24625006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brivaracetam: new compound approved for the treatment of epilepsy.
    Zaccara G
    Drugs Today (Barc); 2016 Apr; 52(4):219-27. PubMed ID: 27252986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of lifetime antiepileptic drug treatment history on efficacy and tolerability of adjunctive brivaracetam in adults with focal seizures: Post-hoc analysis of a randomized, placebo-controlled trial.
    Klein P; McLachlan R; Foris K; Nondonfaz X; Elmoufti S; Dimova S; Brandt C
    Epilepsy Res; 2020 Nov; 167():106369. PubMed ID: 32717713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models.
    Leclercq K; Matagne A; Provins L; Klitgaard H; Kaminski RM
    J Pharmacol Exp Ther; 2020 Jan; 372(1):11-20. PubMed ID: 31619464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy-A monocenter survey.
    Steinhoff BJ; Bacher M; Bucurenciu I; Hillenbrand B; Intravooth T; Kornmeier R; Kurth C; Stockinger J; Staack AM
    Seizure; 2017 May; 48():11-14. PubMed ID: 28364655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: Two double-blind, randomized, multicenter, historical control, Phase III studies.
    Arnold S; Badalamenti V; Diaz A; Gasalla T; McShea C; Whitesides J; Fakhoury T
    Epilepsy Res; 2018 Mar; 141():73-82. PubMed ID: 29486396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.